2025
In early 2025, the Group established Aasthe Mill Bio-Medical R&D Co., Ltd. as its research, development and customization entity for overseas markets, and launched AstheMell as its international trade brand.
The company focuses on mainstream facial fillers and facial rejuvenation products for international markets. Its portfolio covers established overseas product categories, including cross-linked hyaluronic acid fillers, collagen-based implants, PLLA and PDLLA biostimulatory materials, calcium hydroxyapatite and polycaprolactone products, as well as complementary mesotherapy formulations.
Built around one-stop customization, its services span formulation selection and adjustment, packaging and visual design, preparation of registration documentation for target markets, sample development and bulk delivery. The company supports OEM, ODM and OBM partnerships.
In terms of regulatory qualifications, the company organizes its research, development and production processes in accordance with ISO 13485 and GMP quality systems. Relevant facial filler products have obtained CE certification, enabling the company to meet medical device market access requirements in overseas markets.